Company news
Initiator Pharma A/S news in 2026
Initiator Pharma A/S's news releases, calls and decks from 2026, newest first.
Initiator Pharma strengthens its management team – appoints Annette Säfholm as COO
September 14, 2026
Initiator Pharma secures two European patents for pudafensine
August 19, 2026
Initiator Pharma attends BIO 2026 in San Diego
June 23, 2026
Initiator Pharma A/S – Resolutions of the annual general meeting 2026
May 29, 2026
Initiator Pharma A/S calls for the Annual General Meeting
May 12, 2026
Initiator Pharma Q1 2026 Operating Loss DKK 11.4 Mln
May 8, 2026
Initiator Pharma progresses patient enrollment in Phase 2a vulvodynia study
April 28, 2026
Initiator Pharma: Full focus on pudafensine, IP2018 is discontinued
April 21, 2026
Initiator Pharma To Fully Prioritize Pudafensine
April 17, 2026
Initiator Pharma to present at Redeye Healthcare Day 2026
April 10, 2026
INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data expected by 2026
March 11, 2026
INIT: Pudafensine targets major unmet needs in ED and vulvodynia, with pivotal data due in late 2024
March 9, 2026
Initiator Pharma (Q4 Review): Dosing underway in phase IIa study
February 20, 2026
Initiator Pharma Granted European Patent For Pudafensine in FSD
February 18, 2026